Literature DB >> 2569928

Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer.

P M Schneider1, M C Hung, S M Chiocca, J Manning, X Y Zhao, K Fang, J A Roth.   

Abstract

We studied non-small cell lung cancers (NSCLC) from 60 patients for abnormalities in the c-erbB-2 gene. Eleven human lung cancer cell lines, including four derived from small cell lung cancer (SCLC) and seven derived from NSCLC were also examined for altered c-erbB-2 gene expression. Southern blot analysis of paired tumor and normal lung samples demonstrated that amplification of the c-erbB-2 gene is rare in NSCLC (2/60) and not restricted to adenocarcinomas. One patient showed an EcoRI restriction fragment length polymorphism for the c-erbB-2 locus. Four of four SCLC cell lines demonstrated minimal or nondetectable expression of c-erbB-2 mRNA compared to high levels of expression by seven of seven NSCLC lines. The highest expression levels were seen in four of four adenocarcinomas. We conclude that c-erbB-2 expression is different in SCLC compared to NSCLC and high expression of c-erbB-2 is consistently present in lung adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2569928

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

Review 1.  Protein-based tumor molecular imaging probes.

Authors:  Xin Lin; Jin Xie; Xiaoyuan Chen
Journal:  Amino Acids       Date:  2010-03-17       Impact factor: 3.520

Review 2.  HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer.

Authors:  Kazi M Ahmed; Ning Cao; Jian Jian Li
Journal:  Anticancer Res       Date:  2006 Nov-Dec       Impact factor: 2.480

Review 3.  Antibody-based imaging of HER-2: moving into the clinic.

Authors:  R E Wang; Y Zhang; L Tian; W Cai; J Cai
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

Review 4.  New prognostic factors in resectable non-small cell lung cancer.

Authors:  E F Smit; H J Groen; T A Splinter; T Ebels; P E Postmus
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

Review 5.  The neu-protein and breast cancer.

Authors:  C R De Potter; A M Schelfhout
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

6.  Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.

Authors:  G D Lewis; I Figari; B Fendly; W L Wong; P Carter; C Gorman; H M Shepard
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

7.  Arecoline induced disruption of expression and localization of the tight junctional protein ZO-1 is dependent on the HER 2 expression in human endometrial Ishikawa cells.

Authors:  Sarbani Giri; Kevin M Poindexter; Shyam N Sundar; Gary L Firestone
Journal:  BMC Cell Biol       Date:  2010-07-06       Impact factor: 4.241

Review 8.  Preclinical testing of an anti-erbB-2 recombinant toxin.

Authors:  C R King; P G Kasprzyk; P H Fischer; R E Bird; N A Turner
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

9.  In vitro and in vivo expressions of transforming growth factor-alpha and tyrosine kinase receptors in human non-small-cell lung carcinomas.

Authors:  C Liu; M S Tsao
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

10.  Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics.

Authors:  John S Vorhies; John J Nemunaitis
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.